Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20482028 | 0.81 | ALDH1A1 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19631735 | 0.77 | HTR1A (0.39) | HTR1ADRD2DRD3 | |
| SCHEMBL21233704 | 0.77 | TRPV6 (0.43) | ALDH1A1OPRM1 | |
| SCHEMBL22169574 | 0.77 | ALDH1A1 (0.39) | ALDH1A1DRD2OPRM1DRD3 | |
| SCHEMBL22169640 | 0.75 | OPRM1 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22169566 | 0.75 | DRD4 (0.53) | ALDH1A1HTR1ADRD2DRD3 | |
| SCHEMBL19631736 | 0.75 | PRCP (0.47) | CHRM4ALDH1A1DRD2 | |
| SCHEMBL19632043 | 0.74 | DRD2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19631833 | 0.71 | SIGMAR1 (0.41) | CHRM2ALDH1A1OPRM1 | |
| SCHEMBL19632148 | 0.71 | SLC6A4 (0.35) | ALDH1A1DRD2OPRM1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | disclosed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | CHRM2 1110/4885CHRM4 759/4885CHRM5 709/4885 |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | OPRD1, SIGMAR1, OPRK1 | CHRM2 1110/4885CHRM4 759/4885CHRM5 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.